At the news
? NEUTRALIMPACT 3/10 CLUSTER filed May 15, 2026 at 16:05 ET
Two directors at Collegium Pharmaceutical sold a combined $485K in open-market stock within 11 days of the company reporting strong Q1 2026 earnings (revenue +9% YoY, JORNAY PM +36%). The sales are small relative to the $1.1B market cap (~0.04%) and are not clustered with C-suite insiders, making them routine diversification trades rather than informed selling. The earnings report reaffirmed full-year guidance and highlighted the pending AZSTARYS acquisition, which is expected to close in Q2 2026.
- Two directors sold a total of $485K in open-market shares over 4 days (May 11-13, 2026).
- Sales represent ~0.04% of Collegium's $1.1B market cap, immaterial.
- No C-suite insiders (CEO, CFO, etc.) sold shares in the cluster.
- Q1 2026 earnings (filed May 7) showed net revenue of $193.5M (+9% YoY) and JORNAY PM revenue of $38.9M (+36% YoY).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access